Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

China's Zai Lab hits 3-month peak as NMPA approves lung cancer drug

** Shares of Chinese biopharmaceutical group Zai Lab Ltd
 9688.HK  jump as much as 11% to HK$17.98, their highest since
Feb. 2, and on course for fourth consecutive session of gains
    ** Zai Lab says China's National Medical Products
Administration  NMPA  has approved the New Drug Application for
its AUGTYROTM, or repotrectinib, for treatment of adult patients
with metastatic ROS1-positive non-small-cell lung cancer
    ** Company says it has an exclusive license agreement with
Turning Point Therapeutics Inc - a unit of Bristol Myers Squibb
 BMY.N , to develop and commercialize repotrectinib in mainland
China, Hong Kong, Macau and Taiwan
    ** Hong Kong's healthcare index  .HSCIH  slips 0.7%, while
Hang Seng Composite Index  .HSCI  climbs 0.7% and Hang Seng
Index  .HSI  adds 0.5%
    ** Zai Lab stock down 23.8% YTD  

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))

Recent news on Zai Lab

See all news